Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis
Open Access
- 1 June 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (6), 3114-3120
- https://doi.org/10.1128/aac.00384-12
Abstract
Novel oral regimens composed of new drugs with potent activity against Mycobacterium tuberculosis and no cross-resistance with existing agents are needed to shorten and simplify treatment for both drug-susceptible and drug-resistant tuberculosis. As part of a continuing effort to evaluate novel drug combinations for treatment-shortening potential in a murine model, we performed two long-term, relapse-based experiments. In the first experiment, several 3- and 4-drug combinations containing new agents currently in phase 2/3 trials (TMC207 [bedaquiline], PA-824 and PNU-100480 [sutezolid], and/or clofazimine) proved superior to the first-line regimen of rifampin, pyrazinamide, and isoniazid. TMC207 plus PNU-100480 was the most effective drug pair. In the second experiment, in which 3- and 4-drug combinations composed of TMC207 and pyrazinamide plus rifapentine, clofazimine, PNU-100480, or both rifapentine and clofazimine were evaluated, the rank order of drugs improving the sterilizing activity of TMC207 and pyrazinamide was as follows: rifapentine plus clofazimine ≥ clofazimine ≥ rifapentine > PNU-100480. The results revealed potential new building blocks for universally active short-course regimens for drug-resistant tuberculosis. The inclusion of pyrazinamide against susceptible isolates may shorten the duration of treatment further.Keywords
This publication has 46 references indexed in Scilit:
- Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic LesionsThe Journal of Infectious Diseases, 2011
- Pyrazinoic Acid Decreases the Proton Motive Force, Respiratory ATP Synthesis Activity, and Cellular ATP LevelsAntimicrobial Agents and Chemotherapy, 2011
- Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal modelsJournal of Antimicrobial Chemotherapy, 2011
- Comparative Studies Evaluating Mouse Models Used for Efficacy Testing of Experimental Drugs against Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone OxidoreductaseJournal of Biological Chemistry, 2011
- Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for TuberculosisAntimicrobial Agents and Chemotherapy, 2011
- Noninvasive Pulmonary [ 18 F]-2-Fluoro-Deoxy- d -Glucose Positron Emission Tomography Correlates with Bactericidal Activity of Tuberculosis Drug TreatmentAntimicrobial Agents and Chemotherapy, 2009
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialThe Lancet, 2009
- Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment DurationAntimicrobial Agents and Chemotherapy, 2006